Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling

Open access
Zhang, Xiao-Ning, Yang, Kai-Di, Chen, Cong, He, Zhi-Cheng, Wang, Qiang-Hu, Feng, Hua, Lv, Sheng-Qing, Wang, Yan, Mao, Min, Liu, Qing, Tan, Yao-Yao, Wang, Wen-Ying, Li, Tian-Ran, Che, Lin-Rong, Qin, Zhong-Yi, Wu, Ling-Xiang, Luo, Min, Luo, Chun-Hua, Liu, Yu-Qi, Yin, Wen, Wang, Chao, Guo, Hai-Tao, Li, Qing-Rui, Wang, Bin, Chen, Wei, Wang, Shuang, Shi, Yu, Bian, Xiu-Wu, Ping, Yi-Fang · 2021 · Cell Research

Abstract

Glioblastoma (GBM) is a prevalent and highly lethal form of glioma, with rapid tumor progression and frequent recurrence. Excessive outgrowth of pericytes in GBM governs the ecology of the perivascular niche, but their function in mediating chemoresistance has not been fully explored. Herein, we uncovered that pericytes potentiate DNA damage repair (DDR) in GBM cells residing in the perivascular niche, which induces temozolomide (TMZ) chemoresistance. We found that increased pericyte proportion correlates with accelerated tumor recurrence and worse prognosis. Genetic depletion of pericytes in GBM xenografts enhances TMZ-induced cytotoxicity and prolongs survival of tumor-bearing mice. Mechanistically, C-C motif chemokine ligand 5 (CCL5) secreted by pericytes activates C-C motif chemokine receptor 5 (CCR5) on GBM cells to enable DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-mediated DDR upon TMZ treatment. Disrupting CCL5-CCR5 paracrine signaling through the brain-penetrable CCR5 antagonist maraviroc (MVC) potently inhibits pericyte-promoted DDR and effectively improves the chemotherapeutic efficacy of TMZ. GBM patient-derived xenografts with high CCL5 expression benefit from combined treatment with TMZ and MVC. Our study reveals the role of pericytes as an extrinsic stimulator potentiating DDR signaling in GBM cells and suggests that targeting CCL5-CCR5 signaling could be an effective therapeutic strategy to improve chemotherapeutic efficacy against GBM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41422-021-00528-3

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 170

Metadata

Authors
Zhang, X.-N., Yang, K.-D., Chen, C., He, Z.-C., Wang, Q.-H., Feng, H., Lv, S.-Q., Wang, Y., Mao, M., Liu, Q., Tan, Y.-Y., Wang, W.-Y., Li, T.-R., Che, L.-R., Qin, Z.-Y., Wu, L.-X., Luo, M., Luo, C.-H., Liu, Y.-Q., Yin, W., Wang, C., Guo, H.-T., Li, Q.-R., Wang, B., Chen, W., Wang, S., Shi, Y., Bian, X.-W., & Ping, Y.-F.
Venue
Cell Research
Published
2021-07-08
Volume
31
Issue
10
Pages
1072-1087
ISSN
  • 1001-0602 (ISSN-L)
  • 1748-7838
OpenAlex
W3177818413
Cited by
170
References
10
FWCI
11.93
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling. https://app.cochat.ai/papers/10.1038/s41422-021-00528-3
The paper
Zhang, X.-N., Yang, K.-D., Chen, C., He, Z.-C., Wang, Q.-H., Feng, H., Lv, S.-Q., Wang, Y., Mao, M., Liu, Q., Tan, Y.-Y., Wang, W.-Y., Li, T.-R., Che, L.-R., Qin, Z.-Y., Wu, L.-X., Luo, M., Luo, C.-H., Liu, Y.-Q., . . . Ping, Y.-F. (2021). Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling. Cell Research. https://doi.org/10.1038/s41422-021-00528-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.